Factors Associated with Utilization of Dipeptidyl-4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Retrospective Study
Dipeptidyl-4 (DPP-4) inhibitors are oral antidiabetic agents recently introduced to Malaysia. Thus, limited data is available on their utilization patterns and factors associated with their use. This study aims to analyse the utilization patterns of DPP-4 inhibitors, factors that influenced the choi...
Saved in:
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2014-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2014/367564 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832554906655916032 |
---|---|
author | Hasniza Zaman Huri NorFarahen Selamat Shireene Ratna Vethakkan |
author_facet | Hasniza Zaman Huri NorFarahen Selamat Shireene Ratna Vethakkan |
author_sort | Hasniza Zaman Huri |
collection | DOAJ |
description | Dipeptidyl-4 (DPP-4) inhibitors are oral antidiabetic agents recently introduced to Malaysia. Thus, limited data is available on their utilization patterns and factors associated with their use. This study aims to analyse the utilization patterns of DPP-4 inhibitors, factors that influenced the choice of agent, and the rationale for treatment with DPP-4 inhibitors in patients with type 2 diabetes mellitus. This retrospective study was conducted to address the utilization pattern of DPP-4 inhibitors and factors that influence choice in type 2 diabetes mellitus patients. 299 subjects taking either sitagliptin or vildagliptin from September 2008 to September 2012 were included in the study. Sitagliptin was more frequently prescribed than vildagliptin. Of the patients prescribed DPP-4 inhibitors, 95% received combinations of these and other agents, whereas only 5% were prescribed DPP-4 inhibitors as monotherapy. Factors affecting the utilization of DPP-4 inhibitors included age (P=0.049) and concomitant use of beta blockers (P=0.045) and aspirin (P=0.008). Early identification of factors associated with DPP-4 inhibitors is essential to enhance quality use of the drugs. |
format | Article |
id | doaj-art-5089517480f84c9eb6390491ef6d7bee |
institution | Kabale University |
issn | 1687-8337 1687-8345 |
language | English |
publishDate | 2014-01-01 |
publisher | Wiley |
record_format | Article |
series | International Journal of Endocrinology |
spelling | doaj-art-5089517480f84c9eb6390491ef6d7bee2025-02-03T05:50:13ZengWileyInternational Journal of Endocrinology1687-83371687-83452014-01-01201410.1155/2014/367564367564Factors Associated with Utilization of Dipeptidyl-4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Retrospective StudyHasniza Zaman Huri0NorFarahen Selamat1Shireene Ratna Vethakkan2Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, MalaysiaDepartment of Pharmacy, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, MalaysiaEndocrinology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, MalaysiaDipeptidyl-4 (DPP-4) inhibitors are oral antidiabetic agents recently introduced to Malaysia. Thus, limited data is available on their utilization patterns and factors associated with their use. This study aims to analyse the utilization patterns of DPP-4 inhibitors, factors that influenced the choice of agent, and the rationale for treatment with DPP-4 inhibitors in patients with type 2 diabetes mellitus. This retrospective study was conducted to address the utilization pattern of DPP-4 inhibitors and factors that influence choice in type 2 diabetes mellitus patients. 299 subjects taking either sitagliptin or vildagliptin from September 2008 to September 2012 were included in the study. Sitagliptin was more frequently prescribed than vildagliptin. Of the patients prescribed DPP-4 inhibitors, 95% received combinations of these and other agents, whereas only 5% were prescribed DPP-4 inhibitors as monotherapy. Factors affecting the utilization of DPP-4 inhibitors included age (P=0.049) and concomitant use of beta blockers (P=0.045) and aspirin (P=0.008). Early identification of factors associated with DPP-4 inhibitors is essential to enhance quality use of the drugs.http://dx.doi.org/10.1155/2014/367564 |
spellingShingle | Hasniza Zaman Huri NorFarahen Selamat Shireene Ratna Vethakkan Factors Associated with Utilization of Dipeptidyl-4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Retrospective Study International Journal of Endocrinology |
title | Factors Associated with Utilization of Dipeptidyl-4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Retrospective Study |
title_full | Factors Associated with Utilization of Dipeptidyl-4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Retrospective Study |
title_fullStr | Factors Associated with Utilization of Dipeptidyl-4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Retrospective Study |
title_full_unstemmed | Factors Associated with Utilization of Dipeptidyl-4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Retrospective Study |
title_short | Factors Associated with Utilization of Dipeptidyl-4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Retrospective Study |
title_sort | factors associated with utilization of dipeptidyl 4 inhibitors in patients with type 2 diabetes mellitus a cross sectional retrospective study |
url | http://dx.doi.org/10.1155/2014/367564 |
work_keys_str_mv | AT hasnizazamanhuri factorsassociatedwithutilizationofdipeptidyl4inhibitorsinpatientswithtype2diabetesmellitusacrosssectionalretrospectivestudy AT norfarahenselamat factorsassociatedwithutilizationofdipeptidyl4inhibitorsinpatientswithtype2diabetesmellitusacrosssectionalretrospectivestudy AT shireeneratnavethakkan factorsassociatedwithutilizationofdipeptidyl4inhibitorsinpatientswithtype2diabetesmellitusacrosssectionalretrospectivestudy |